1. Home
  2. IHD vs GNLX Comparison

IHD vs GNLX Comparison

Compare IHD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Emerging Markets High Income Dividend Equity Fund

IHD

Voya Emerging Markets High Income Dividend Equity Fund

HOLD

Current Price

$6.75

Market Cap

112.6M

Sector

Finance

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.50

Market Cap

202.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHD
GNLX
Founded
2011
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.6M
202.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
IHD
GNLX
Price
$6.75
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.75
AVG Volume (30 Days)
27.7K
377.3K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
10.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.49
$1.99
52 Week High
$5.47
$8.54

Technical Indicators

Market Signals
Indicator
IHD
GNLX
Relative Strength Index (RSI) 56.35 29.26
Support Level $6.76 $2.61
Resistance Level $7.09 $2.97
Average True Range (ATR) 0.09 0.18
MACD -0.02 0.05
Stochastic Oscillator 19.97 6.15

Price Performance

Historical Comparison
IHD
GNLX

About IHD Voya Emerging Markets High Income Dividend Equity Fund

Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: